Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens

被引:19
作者
Akbari, Mohammad R. [1 ]
Zhang, Shiyu [1 ]
Cragun, Deborah [2 ]
Lee, Ji-Hyun [2 ]
Coppola, Domenico [2 ]
McLaughlin, John [3 ,4 ]
Risch, Harvey A. [5 ]
Rosen, Barry [6 ,7 ]
Shaw, Patricia [8 ]
Sellers, Thomas A. [2 ]
Schildkraut, Joellen [9 ]
Narod, Steven A. [1 ]
Pal, Tuya [2 ]
机构
[1] Univ Toronto, Womens Coll Res Inst, Womens Coll Hosp, 790 Bay St,7th Floor, Toronto, ON M5G 1N8, Canada
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Biostat Anat Pathol & Expt Therapeut, 12902 Magnolia Dr, Tampa, FL 33612 USA
[3] Univ Toronto, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada
[4] Univ Toronto, Dalla Lana Sch Publ Hlth, 600 Univ Ave, Toronto, ON M5G 1X5, Canada
[5] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St, New Haven, CT 06510 USA
[6] Univ Toronto, Princess Margaret Hosp, Dept Gynecol Oncol, 610 Univ Ave, Toronto, ON M5T 2M9, Canada
[7] Univ Toronto, Fac Med, Dept Obstet & Gynecol, 610 Univ Ave, Toronto, ON M5T 2M9, Canada
[8] Princess Margaret Hosp, Dept Pathol, 610 Univ Ave, Toronto, ON M5T 2M9, Canada
[9] Duke Univ, Dept Community & Family Med, Duke Comprehens Canc Ctr, Med Ctr, Box 2949, Durham, NC 27710 USA
关键词
Ovarian cancer; Microsatellite Instability; TESTING STRATEGIES; BRCA2; MUTATIONS; LYNCH SYNDROME; POPULATION; CRITERIA; WOMEN; RISK; MLH1; MSH2;
D O I
10.1007/s10689-017-9973-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A high proportion of ovarian cancers from women who carry germline mutations in mismatch repair (MMR) genes demonstrate microsatellite instability (MSI). The utility of pre-screening ovarian cancer specimens for MSI to identify potential patients for germline screening for MMR mutations is uncertain. 656 women with malignant ovarian cancer underwent both MSI testing and germline mutation testing for large rearrangements in three MMR genes, MLH1, MSH2 and MSH6. Germline DNA sequencing data for the same genes was available. Among the 656 women, only four (0.6%) carried a clearly pathogenic MMR mutation. All four cancers from patients with mutations had loss of two or more microsatellite markers (MSI-high). Eighty-four of 652 (13.0%) women without a mutation had MSI-high ovarian cancers. Using MSI-high as a prescreening criterion, the sensitivity of MSI testing to identify germline MMR gene mutations was 100% and the positive predictive value was 4.5%. Germline mutations in MLH1, MSH2 and MSH6 are rare among unselected cases of ovarian cancer. Patients with germline mutations often will have MSI-positive cancers and pre-screening of ovarian cancer specimens may be an efficient way of identifying patients with Lynch syndrome.
引用
收藏
页码:351 / 355
页数:5
相关论文
共 23 条
[1]  
Berg AO, 2009, GENET MED, V11, P35, DOI [10.1097/GIM.0b013e318181fa2ff, 10.1097/GIM.0b013e31818fa2ff]
[2]  
Boland CR, 1998, CANCER RES, V58, P5248
[3]   Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome [J].
Bonadona, Valerie ;
Bonaiti, Bernard ;
Olschwang, Sylviane ;
Grandjouan, Sophie ;
Huiart, Laetitia ;
Longy, Michel ;
Guimbaud, Rosine ;
Buecher, Bruno ;
Bignon, Yves-Jean ;
Caron, Olivier ;
Colas, Chrystelle ;
Nogues, Catherine ;
Lejeune-Dumoulin, Sophie ;
Olivier-Faivre, Laurence ;
Polycarpe-Osaer, Florence ;
Nguyen, Tan Dat ;
Desseigne, Francoise ;
Saurin, Jean-Christophe ;
Berthet, Pascaline ;
Leroux, Dominique ;
Duffour, Jacqueline ;
Manouvrier, Sylvie ;
Frebourg, Thierry ;
Sobol, Hagay ;
Lasset, Christine ;
Bonaiti-Pellie, Catherine .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2304-2310
[4]   Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering [J].
Browning, Sharon R. ;
Browning, Brian L. .
AMERICAN JOURNAL OF HUMAN GENETICS, 2007, 81 (05) :1084-1097
[5]   Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer [J].
de Jong, AE ;
van Puijenbroek, M ;
Hendriks, Y ;
Tops, C ;
Wijnen, J ;
Ausems, MGEM ;
Meijers-Heijboer, H ;
Wagner, A ;
van Os, TAM ;
Bröcker-Vriends, AHJT ;
Vasen, HFA ;
Morreau, H .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :972-980
[6]   Deletions Removing the Last Exon of TACSTD1 Constitute a Distinct Class of Mutations Predisposing to Lynch Syndrome [J].
Kovacs, Marietta E. ;
Papp, Janos ;
Szentirmay, Zoltan ;
Otto, Szabolcs ;
Olah, Edith .
HUMAN MUTATION, 2009, 30 (02) :197-203
[7]   Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome - A systematic review [J].
Lindor, Noralane M. ;
Petersen, Gloria M. ;
Hadley, Donald W. ;
Kinney, Anita Y. ;
Miesfeldt, Susan ;
Lu, Karen H. ;
Lynch, Patrick ;
Burke, Wylie ;
Press, Nancy .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (12) :1507-1517
[8]   The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer [J].
Mvundura, Mercy ;
Grosse, Scott D. ;
Hampel, Heather ;
Palomaki, Glenn E. .
GENETICS IN MEDICINE, 2010, 12 (02) :93-104
[9]   Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial [J].
Narod, Steven A. ;
Giannakeas, Vasily ;
Sopik, Victoria .
GYNECOLOGIC ONCOLOGY, 2016, 141 (02) :191-194
[10]   BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases [J].
Pal, T ;
Permuth-Wey, J ;
Betts, JA ;
Krischer, JP ;
Fiorica, J ;
Arango, H ;
LaPolla, J ;
Hoffman, M ;
Martino, MA ;
Wakeley, K ;
Wilbanks, G ;
Nicosia, S ;
Cantor, A ;
Sutphen, R .
CANCER, 2005, 104 (12) :2807-2816